Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

A Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C Treatment.

Kempker RR, Alghamdi WA, Al-Shaer MH, Burch G, Peloquin CA.

Antimicrob Agents Chemother. 2019 Oct 7. pii: AAC.01215-19. doi: 10.1128/AAC.01215-19. [Epub ahead of print] Review.

PMID:
31591118
2.

Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples.

Al-Shaer MH, Alghamdi WA, Graham E, Peloquin CA.

Ther Drug Monit. 2019 Jul 15. doi: 10.1097/FTD.0000000000000675. [Epub ahead of print]

PMID:
31318843
3.

Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.

Al-Shaer MH, Alghamdi WA, Alsultan A, An G, Ahmed S, Alkabab Y, Banu S, Barbakadze K, Houpt E, Kipiani M, Mikiashvili L, Cegielski JP, Kempker RR, Heysell SK, Peloquin CA.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00279-19. doi: 10.1128/AAC.00279-19. Print 2019 Jul.

4.

Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis.

Alghamdi WA, Alsultan A, Al-Shaer MH, An G, Ahmed S, Alkabab Y, Banu S, Barbakadze K, Houpt E, Kipiani M, Mikiashvili L, Schmidt S, Heysell SK, Kempker RR, Cegielski JP, Peloquin CA.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e00055-19. doi: 10.1128/AAC.00055-19. Print 2019 May.

5.
6.

Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis.

Lange C, Alghamdi WA, Al-Shaer MH, Brighenti S, Diacon AH, DiNardo AR, Grobbel HP, Gröschel MI, von Groote-Bidlingmaier F, Hauptmann M, Heyckendorf J, Köhler N, Kohl TA, Merker M, Niemann S, Peloquin CA, Reimann M, Schaible UE, Schaub D, Schleusener V, Thye T, Schön T.

J Intern Med. 2018 May 28. doi: 10.1111/joim.12780. [Epub ahead of print]

PMID:
29806961
7.

Protein Binding of First-Line Antituberculosis Drugs.

Alghamdi WA, Al-Shaer MH, Peloquin CA.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00641-18. doi: 10.1128/AAC.00641-18. Print 2018 Jul.

8.

Pharmacokinetics of tuberculosis drugs in HIV-infected patients from Irkutsk, Russian Federation: redefining drug activity.

Lyles G, Ogarkov O, Zhdanova S, Peloquin CA, Ebers A, Pfaeffle H, Al-Shaer MH, Moiseeva E, Zorkaltseva E, Koscheev M, Houpt ER, Heysell SK.

Eur Respir J. 2018 May 24;51(5). pii: 1800109. doi: 10.1183/13993003.00109-2018. Print 2018 May. No abstract available.

9.

Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?

Alfarisi O, Alghamdi WA, Al-Shaer MH, Dooley KE, Peloquin CA.

Expert Rev Clin Pharmacol. 2017 Oct;10(10):1027-1036. doi: 10.1080/17512433.2017.1366311. Epub 2017 Aug 18. Review.

PMID:
28803492
10.

Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar.

Al-Shaer MH, Mansour H, Elewa H, Salameh P, Iqbal F.

BMC Infect Dis. 2017 Feb 2;17(1):118. doi: 10.1186/s12879-017-2231-1.

11.

Metoclopramide-induced asystolic cardiac arrest.

Al-Shaer MH, Mustafa MS, Scalese MJ.

Ann Pharmacother. 2015 May;49(5):610-1. doi: 10.1177/1060028015577446. No abstract available.

PMID:
25870445
12.

Outcomes of care by hospitalists.

Al-Shaer MH, Suleiman ES, Jerome WP.

N Engl J Med. 2008 Apr 17;358(16):1755-6; author reply 1757-8. doi: 10.1056/NEJMc080089. No abstract available.

PMID:
18420512
13.

The appropriateness of nicotinic acid derivative use in patients with the metabolic syndrome: insights from the ARBITER 2 study.

Al-Shaer MH, Jerome WP.

Am J Cardiol. 2006 Jul 15;98(2):275-6. Epub 2006 Mar 9. No abstract available.

PMID:
16828609
14.

Effects of aging and atherosclerosis on endothelial and vascular smooth muscle function in humans.

Al-Shaer MH, Choueiri NE, Correia ML, Sinkey CA, Barenz TA, Haynes WG.

Int J Cardiol. 2006 May 10;109(2):201-6. Epub 2005 Jul 27.

PMID:
16054252
15.
16.

The impact of ethnicity on the lifetime risk of the metabolic syndrome and diabetes mellitus.

Al-Shaer MH, Abusabha H.

Am J Cardiol. 2005 Mar 15;95(6):819-20. No abstract available.

PMID:
15757626
17.

Effect of hyperhomocysteinemia induced by methionine administration on flow-mediated dilatation of the brachial artery in healthy subjects.

Al-Shaer MH, Raghuveer G, Browning R, Sinkey CA, Chenard C, Stumbo P, Haynes WG.

Am J Cardiol. 2005 Feb 1;95(3):428-30.

PMID:
15670563
18.
19.

The pivotal role of cholesterol absorption inhibitors in the management of dyslipidemia.

Al-Shaer MH, Choueiri NE, Suleiman ES.

Lipids Health Dis. 2004 Oct 7;3:22.

20.

The effects of ezetimibe on the LDL-cholesterol particle number.

Al-Shaer MH.

Cardiovasc Drugs Ther. 2004 Jul;18(4):327-8. No abstract available.

PMID:
15367831
21.

C-reactive protein and risk of colon cancer.

Al-Shaer MH.

JAMA. 2004 Jun 16;291(23):2819; author reply 2819. No abstract available.

PMID:
15199030

Supplemental Content

Loading ...
Support Center